Remove Article Remove HIV Treatment and Prevention Agents Remove Vaccines
article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

COVID vaccines and treatments have created a substantial market over and above the existing Rx market- IQVIA estimates that the cumulative value of COVID vaccines could be between $185 and 295bn to 2026. The initial pandemic lockdowns prevented many patients from seeing doctors face-to-face.

article thumbnail

Oral COVID Agents

Pharmacy Friday Pearls

18 years Administration Oral Oral Oral PK/PD MOA: Nirmatrelvir – inhibitor of the SARS-CoV-2 main protease Prevents viral replicationRitonavir is a CYP3A inhibitor included to increase nirmatrelvir plasma levelsRitonavir alone has NO activity against SARS-CoV-2 Time to peak: Nirmatrelvir: 3 hrs & Ritonavir: 3.98 Introduction.

article thumbnail

Ivermectin: A therapeutic approach to reduce high-risk cases of COVID

Druggist

With an ongoing vaccination program globally, experts hope that a large world population will soon get a vaccine that protects against corona. Additionally, this drug is also known as anti-parasite successful against all viruses like HIV, Dengue, Influenza , and Zika virus. Treatment without a prescription can be harmful.